09/724,613

## FILE 'HOME' ENTERED AT 11:21:14 ON 29 AUG 2005

=> file biosis medline caplus wpids uspatfull COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 11:21:27 ON 29 AUG 2005 Copyright (c) 2005 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 11:21:27 ON 29 AUG 2005

FILE 'CAPLUS' ENTERED AT 11:21:27 ON 29 AUG 2005 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 11:21:27 ON 29 AUG 2005 COPYRIGHT (C) 2005 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 11:21:27 ON 29 AUG 2005
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

\*\*\* YOU HAVE NEW MAIL \*\*\*

=> s l1 and protease

L2 9 L1 AND PROTEASE

=> dup rem 12

PROCESSING COMPLETED FOR L2

L3 6 DUP REM L2 (3 DUPLICATES REMOVED)

=> d 13 bib abs 1-6

L3 ANSWER 1 OF 6 WPIDS COPYRIGHT 2005 THE THOMSON CORP on STN DUPLICATE 1

AN 2005-099961 [11] WPIDS

CR 2003-370730 [35]

DNN N2005-086813 DNC C2005-033420

Isolating nucleic acids from a biological sample by combining the sample with at least one cationic surfactant, at least one protease, and a buffer, to form a reaction composition.

DC A89 B04 D16 P53

IN GREENFIELD, L; MONTESCLAROS, L

PA (APPL-N) APPLERA CORP

CYC 1

PI US 2005009045 A1 20050113 (200511) \* 58

ADT US 2005009045 A1 CIP of US 2000-724613 20001128, Cont of US 2001-997169 20011128, US 2004-800137 20040311

FDT US 2005009045 A1 Cont of US 6762027

PRAI US 2001-997169 20011128; US 2000-724613 20001128;

US 2004-800137 20040311

AN 2005-099961 [11] WPIDS

· CR 2003-370730 [35]

AB US2005009045 A UPAB: 20050217

NOVELTY - Isolating nucleic acids from a biological sample comprising combining the sample with at least one cationic surfactant, at least one protease, and a buffer, to form a reaction composition, incubating the reaction composition at a

a reaction composition, incubating the reaction composition at a temperature suitable for releasing nucleic acid from the biological sample, and isolating the released nucleic acid, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

- (1) releasing nucleic acids from a biological sample, comprising:
- (a) combining the sample with at least one cationic

surfactant, at least one protease, and a buffer, to form a reaction composition; and

- '(b) incubating the reaction composition at a temperature suitable for releasing the nucleic acids from the biological sample; and
- (2) a kit for obtaining nucleic acid from a biological sample comprising at least one cationic surfactant and at least one protease.

USE - The methods and compositions of the present invention are useful for isolating and releasing nucleic acids from biological samples, including whole tissue.

ADVANTAGE - The methods of isolating nucleic acids in the present invention, as compared to prior art, reduces the time needed for sample preparation, decreases potential safety risks posed by multi-step procedures and provides high integrity high molecular weight nucleic acids.

Dwg.0/30

```
L3
    ANSWER 2 OF 6 USPATFULL on STN
```

AN2005:93362 USPATFULL

TITreatment of tissue, instruments and work surfaces to remove infectious agents

Cunanan, Crystal M., Mission Viejo, CA, UNITED STATES IN Dinh, Tan Thanh, Fountain Valley, CA, UNITED STATES Loshbaugh, Christine, Irvine, CA, UNITED STATES Sarner, H. Chris, Laguna Hills, CA, UNITED STATES Helmus, Michael N., Worcester, MA, UNITED STATES

US 2005080040 PIA1 20050414

ΑI US 2004-959549 A1 20041005 (10)

Division of Ser. No. US 2001-930619, filed on 15 Aug 2001, ABANDONED

 $\operatorname{DT}$ Utility

RLI

AN

FS APPLICATION

John Christopher James, Edwards Lifesciences LLC, Law Dept., One Edwards LREP Way, Irvine, CA, 92614, US

CLMN Number of Claims: 7  $\mathsf{ECL}$ Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1261

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ABThe present invention provides methods of inactivating and removing infectious agents from tissues of use in bioprosthetic devices. The methods include the removal and blockage of binding sites on the tissues for the infectious agents. Also provided are methods for blocking a site on an infectious agent that binds to a site on the tissue.

## CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
L3
     ANSWER 3 OF 6 USPATFULL on STN
```

2003:71989 USPATFULL

Treatment of tissue, instruments and work surfaces to remove infectious agents

IN Cunanan, Crystal M., Mission Viejo, CA, UNITED STATES Dinh, Tan Thanh, Fountain Valley, CA, UNITED STATES Loshbaugh, Christine, Irvine, CA, UNITED STATES Sarner, H. Chris, Laguna Hills, CA, UNITED STATES Helmus, Michael N., Worcester, MA, UNITED STATES

PIUS 2003050276 **A**1 20030313 ΑI

US 2001-930619 20010815 (9) **A**1

DTUtility

FS APPLICATION

Edwards Lifesciences LLC, Law Dept., One Edwards Way, Irvine, CA, 92614 LREP

CLMN Number of Claims: 49

 $\mathsf{ECL}$ Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1331

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ABThe present invention provides methods of inactivating and removing infectious agents from tissues of use in bioprosthetic devices. The methods include the removal and blockage of binding sites on the tissues for the infectious agents. Also provided are methods for blocking a site on an infectious agent that binds to a site on the tissue.

## CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
ANSWER 4 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 2
L3
AN
     2002:869079 CAPLUS
     137:365972
DN
     Isolation of nucleic acids from biological samples using surfactants and
TI
    proteases
    Greenfeld, I. Larry
IN
    PE Corporation, USA; Applera Corporation
PA
SO
     PCT Int. Appl., 129 pp.
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN. CNT 2
     PATENT NO.
                        KIND
                               DATE
                                          APPLICATION NO.
                                                                 DATE
                                           ------
                        ----
     _____
                               -----
    WO 2002090539
                        A2
                                          WO 2001-US45071 20011128
PI
                               20021114
                        A3
                               20030807
    WO 2002090539
        W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
            CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
            GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
            LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
            PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
            UG, UZ, VN, YU, ZA, ZM, ZW
        RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
            KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
            GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
            GN, GQ, GW, ML, MR, NE, SN, TD, TG
     CA 2429941
                         AA
                               20021114
                                           CA 2001-2429941
                                                                 20011128
                         A2
                               20031022
                                           EP 2001-274041
     EP 1354036
                                                                 20011128
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
                         T2
                                        JP 2002-587600
                                                                 20011128
     JP 2005501523
                               20050120
PRAI US 2000-724613
                         Α
                               20001128
    WO 2001-US45071
                         W
                               20011128
    The invention relates to compns. and methods for isolating nucleic acids
AB
     from biol. samples, including whole tissue. The
     method comprises contacting the biol. sample with a disrupting buffer
     containing proteases (e.g., Proteinase K) and a cationic
     surfactant (e.g., CTAB). The cationic
     surfactant is then neutralized either by its removal or by use of
     a second nonionic surfactants (e.g., Tween 20). Nucleic acids are then
     isolated by binding to a solid phase, such as glass fiber GF/B filters.
    The effects of cationic surfactants on activity of
    proteinase K, and the solubility of surfactants in different chaotropes is
     investigated to identify optimal cationic surfactants
     and salts. The invention also provides kits for isolating nucleic acids
     from biol. samples.
    ANSWER 5 OF 6 CAPLUS COPYRIGHT 2005 ACS on STN DUPLICATE 3
L3
AN
     2002:907069 CAPLUS
DN
    138:1959
    Compositions, methods, and kits for isolating nucleic acids using
TI
     surfactants and proteases
IN
    Greenfield, Lawrence; Montesclaros, Luz
PΑ
    Applera Corp., USA
    U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S. Ser. No. 724,613.
SO
     CODEN: USXXCO
DT
     Patent
LА
     English
FAN.CNT 2
     PATENT NO.
                        KIND
                                          APPLICATION NO.
                                                                 DATE
                               DATE
                        ----
                               -----
                               20021128
PI
    US 2002177139
                       A1
                                          US 2001-997169
                                                                 20011128
                         B2
    US 6762027
                               20040713
```

US 2005009045 **A**1 20050113 US 2004-800137 20040311 PRAI US 2000-724613 A2 20001128 · US 2001-997169 A1 20011128 The invention relates to compns. and methods for isolating nucleic acids ABfrom biol. samples, including whole tissue. The invention also provides kits for isolating nucleic acids from biol. samples. A method for obtaining nucleic acid from a biol. sample and binding the nucleic acid to a solid phase comprises (a) contacting the biol sample with a disrupting buffer, wherein the disrupting buffer comprises a protease and a cationic surfactant ; (b) substantially neutralizing the cationic surfactant ; and (c) binding the nucleic acid to a solid phase. Genomic DNA was isolated from several rat tissues and mouse tail using a digestion solution containing 1 mg of Proteinase K, 1 % DTAB, 100 mM Tris-HCl (pH 8.0), 20 µM ATA, and 20 mM CaCl2 and incubating for 60 min at 65°. Most of the tissues were effectively digested in less than one hour. Digestion of liver, brain and kidney were about 95 % complete after one hour. Following digestion, binding solution containing 5 M GuSCN, 50 mM MES (pH 6.0), 20 mM EDTA, and 6 % Tween 20 was then added to each sample and the samples were placed on GF/B filter membranes for washing and recovery of DNA. RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT L3ANSWER 6 OF 6 USPATFULL on STN ΑŅ 2002:251081 USPATFULL Methods for preparation of bioprosthetic tissue and implantable devices TI comprising such bioprosthetic tissue Cunanan, Crystal M., Mission Viejo, CA, UNITED STATES INDinh, Tan Thanh, Fountain Valley, CA, UNITED STATES Loshbaugh, Christine, Irvine, CA, UNITED STATES Sarner, H. Chris, Laguna Hills, CA, UNITED STATES Helmus, Michael N., Worcester, MA, UNITED STATES

Cabiling, Christine M., Tustin, CA, UNITED STATES PI US 2002137024 A1 20020926

AI US 2001-4624 A1 20011101 (10)

RLI Continuation-in-part of Ser. No. US 2001-930619, filed on 15 Aug 2001, PENDING

PRAI US 2000-244889P 20001101 (60)

DT Utility

FS APPLICATION

LREP Edwards Lifesciences LLC, Law Dept., One Edwards Way, Irvine, CA, 92614

CLMN Number of Claims: 60

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1761

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

The present invention provides methods of inactivating and removing infectious agents from tissues of use in bioprosthetic devices. The methods include the removal and blockage of binding sites on the tissues for the infectious agents. Also provided are methods for blocking a site on an infectious agent that binds to a site on the tissue. The invention also provides a method for preventing or reducing the calcification of a bioprosthetic tissue. The method includes removing or blocking a phospholipid calcium nucleation site from the tissue.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.